GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (NYSE:BLCO) » Definitions » Preferred Dividends

Bausch & Lomb (Bausch & Lomb) Preferred Dividends : $0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Bausch & Lomb's preferred dividends for the three months ended in Mar. 2024 was $0 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2024 was $0 Mil.


Bausch & Lomb Preferred Dividends Historical Data

The historical data trend for Bausch & Lomb's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Preferred Dividends Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Preferred Dividends
Get a 7-Day Free Trial - - - - -

Bausch & Lomb Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Bausch & Lomb Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.


Bausch & Lomb  (NYSE:BLCO) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bausch & Lomb (Bausch & Lomb) Business Description

Traded in Other Exchanges
Address
520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Executives
Luc Bonnefoy officer: President,Surgical C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Andrew J. Stewart officer: See remarks C/O BAUSCH + LOMB CORPORATION, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Bailey A Robert D officer: EVP & Chief Legal Officer C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Brent L Saunders director, officer: CEO and Chair 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Brett Icahn director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Gaoxiang Hu director 16690 COLLINS AVE., SUITE PH-1, SUNNY ISLES BEACH FL 33160
Bausch Health Companies Inc. 10 percent owner 2150 ST. ELZEAR BLVD. WEST, LAVAL, QUEBEC A8 H7L 4A8
Sarah B Kavanagh director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Nathalie D. Bernier director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Yehia Hashad officer: EVP, R&D and CMO C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE 10, ALACHUA FL 32615
Frederick Munsch officer: SVP, Controller and CAO C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon officer: Please see remarks C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Ross Thomas W. Sr. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann officer: Please see remarks C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Russel C Robertson director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807

Bausch & Lomb (Bausch & Lomb) Headlines

From GuruFocus

Bausch + Lomb Announces Key Leadership Changes

By Business Wire Business Wire 06-01-2023